ER antagonists (e.g., tamoxifen, ICI 182,780) exert effects on breast cancer cells similar to those of aromatase inhibitors; i.e., they block the suppressive effect of estradiol on NF-κB-responsive genes [61,97]. Here, ESR1 is linked to breast carcinoma.